RTTNews | Jul 20, 2020 04:45PM EDT

04:45 Monday, July 20, 2020

|BEGINSUB|Asian Shares Mixed In Cautious Trade|ENDSUB|Asian stocks ended mixed on Monday as EU leaders remained at odds over how to carve up a 750 billion-euro stimulus package designed to help haul Europe out of its deepest recession since World War II. Uncertainty over U.S. stimulus and weak Japanese exports data also kept underlying sentiment cautious.

|BEGINSUB|European Stocks Close Higher On Vaccine Hopes, Stimulus Optimism|ENDSUB|European markets closed higher on Monday, as stocks gained in strength after a weak start, amid optimism about a potential coronavirus vaccine and on hopes the EU leaders will eventually agree on the size and composition of a proposed recovery fund.

|BEGINSUB|Nasdaq Soars To New Record Closing High, Dow Closes Slightly Higher|ENDSUB|Stocks moved mostly higher over the course of the course of the trading session on Monday following the mixed performance last week. The tech-heavy Nasdaq showed a particularly strong upward move, reaching a new record closing high.

|BEGINSUB|Ford, Mobileye To Collaborate On Driver-assistance Systems |ENDSUB|Ford Motor Co. said it has expanded its partnership with Mobileye, a subsidiary of Intel, to collaborate on offering driver-assistance systems across Fords global product lineup.

According to Ford, Mobileye is the chosen supplier of vision-sensing technology for Fords advanced driver-assistance systems or ADAS.

|BEGINSUB|Stock Alert: Verona Pharma Loses 14% |ENDSUB|Shares of UK-based clinical-stage biopharmaceutical company Verona Pharma plc are falling more than 14 percent or $1.47 in Monday's morning trade at $8.73, after recording strong gains in the previous trading session on Friday.

Verona Pharmas stock had surged on Friday following news that it raised about $200 million in an oversubscribed private placement and subscription with new as well as existing institutional and accredited investors. The company plans to initiate a phase III program of Ensifentrine in chronic obstructive pulmonary disease, dubbed ENHANCE, later this year.

For comments and feedback: contact editorial@rttnews.comCopyright(c) 2008 RealTimeTraders.com, Inc. All Rights Reserved